EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ERAS: Erasca Inc

24 Mar 26 15:57
LAST:

14.74

CHANGE:
 0.42		OPEN:
14.53		HIGH:
14.95		ASK:
0.00		VOLUME:
2.66M
CHG(%):
2.90		PREV:
14.32		LOW:
13.86		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Mar 2614.5314.9513.8614.742.66M
23 Mar 2614.6515.2914.2014.325.19M
20 Mar 2615.3615.4614.5814.6017.31M
19 Mar 2613.3815.2913.3615.266.59M
18 Mar 2613.3613.9913.1613.504.69M
17 Mar 2613.5113.6312.9113.365.89M
16 Mar 2614.1514.2813.4813.515.91M
13 Mar 2615.1515.5613.5413.625.35M
12 Mar 2615.3015.5614.1914.656.99M
11 Mar 2615.4015.7715.2215.504.77M

PROFILE

Name:Erasca Inc
About:Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Sector:Healthcare
Industry:Biotechnology
Address:3115 Merryfield Row, San Diego, CA, United States, 92121
Website:https://www.erasca.com
CUSIP:29479A108
CIK:0001761918
ISIN:US29479A1088
FIGI:BBG00MTSR883

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-3.45 
Forward P/E:-10.87 
PEG Ratio:0.06 
Price to Book:4.22 
Return on Assets:-0.18 
Return on Equity:-0.31 
EPS Ratio:-0.61 
Shares:283.71M 
Market Cap:4.18B 

TECHNICAL INDICATORS

MA5:14.481.8%
MA10:14.303.0%
MA20:14.491.7%
MA50:12.3119.7%
MA100:7.7689.9%
MA200:4.74210.8%
STO9:61.82
STO14:44.66
RSI14:46.88
WPR14:-43.33
MTM14:-0.82
ROC14:-0.05 
ATR:1.12 
Week High:15.464.9%
Week Low:12.9114.1%
Month High:16.4111.3%
Month Low:12.84210.8%
Year High:16.4111.3%
Year Low:1.011,358.9%